Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Breast Cancer
Interventions
DRUG

BIIB021

BID orally for 28 days

DRUG

BIIB021

TIW orally for 28 days

DRUG

exemestane (Aromasin)

Daily in tablet form for 28 days

Trial Locations (34)

78229

Research Site, San Antonio

92024

Research Site, Encinitas

Unknown

Research Site, Alabaster

Research Site, Encinitas

Research Site, Gilroy

Research Site, Long Beach

Research Site, Davie

Research Site, Orlando

Research Site, Rochester

Research Site, St Louis

Research Site, Berkeley Heights

Research Site, New York

Research Site, Fargo

Research Site, Columbus

Research Site, Pittsburgh

Research Site, Nashville

Research Site, El Paso

Research Site, Houston

Research Site, Lacey

Research Site, Waratah

Research Site, Wollongong

Research Site, Herston

Research Site, Redcliffe

Research Site, Hobart

Research Site, Geelong

Research Site, Brasschaat

Research Site, Edegem

Research Site, Kortrijk

Research Site, Liège

Research Site, Mons

Research Site, Kuzmolovskiy

Research Site, Moscow

Research Site, Ryazan

Research Site, Saint Petersburg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY